OLINVYK Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Olinvyk, and what generic alternatives are available?
Olinvyk is a drug marketed by Trevena and is included in one NDA. There are five patents protecting this drug.
This drug has fifty-one patent family members in twenty-three countries.
The generic ingredient in OLINVYK is oliceridine. One supplier is listed for this compound. Additional details are available on the oliceridine profile page.
DrugPatentWatch® Generic Entry Outlook for Olinvyk
Olinvyk will be eligible for patent challenges on October 30, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 23, 2032. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for OLINVYK
| International Patents: | 51 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 32 |
| Patent Applications: | 56 |
| Drug Prices: | Drug price information for OLINVYK |
| What excipients (inactive ingredients) are in OLINVYK? | OLINVYK excipients list |
| DailyMed Link: | OLINVYK at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for OLINVYK
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for OLINVYK
US Patents and Regulatory Information for OLINVYK
OLINVYK is protected by five US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of OLINVYK is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting OLINVYK
Opioid receptor ligands and methods of using and making same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
Opioid receptor ligands and methods of using and making same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
Opioid receptor ligands and methods of using and making same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
Opioid receptor ligands and methods of using and making same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
FDA Regulatory Exclusivity protecting OLINVYK
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-001 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-003 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-002 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-001 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-002 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-002 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Trevena | OLINVYK | oliceridine | SOLUTION;INTRAVENOUS | 210730-003 | Oct 30, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for OLINVYK
When does loss-of-exclusivity occur for OLINVYK?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 12230761
Estimated Expiration: ⤷ Sign Up
Patent: 17200745
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2013024136
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 30742
Estimated Expiration: ⤷ Sign Up
China
Patent: 3702561
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0171021
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 19057
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 88403
Estimated Expiration: ⤷ Sign Up
Patent: 90415
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 5456
Estimated Expiration: ⤷ Sign Up
Patent: 1391332
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 88403
Estimated Expiration: ⤷ Sign Up
Patent: 90415
Estimated Expiration: ⤷ Sign Up
Patent: 72076
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 50984
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 32948
Estimated Expiration: ⤷ Sign Up
Patent: 54055
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 8506
Estimated Expiration: ⤷ Sign Up
Patent: 3318
Estimated Expiration: ⤷ Sign Up
Patent: 2165
Estimated Expiration: ⤷ Sign Up
Patent: 4407
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 12169
Estimated Expiration: ⤷ Sign Up
Patent: 43949
Estimated Expiration: ⤷ Sign Up
Patent: 49341
Estimated Expiration: ⤷ Sign Up
Patent: 23683
Estimated Expiration: ⤷ Sign Up
Patent: 48750
Estimated Expiration: ⤷ Sign Up
Patent: 14508811
Estimated Expiration: ⤷ Sign Up
Patent: 16155843
Estimated Expiration: ⤷ Sign Up
Patent: 18048193
Estimated Expiration: ⤷ Sign Up
Patent: 20073570
Estimated Expiration: ⤷ Sign Up
Patent: 21176885
Estimated Expiration: ⤷ Sign Up
Patent: 23075282
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 88403
Estimated Expiration: ⤷ Sign Up
Montenegro
Patent: 754
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 5993
Estimated Expiration: ⤷ Sign Up
Patent: 3143
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 88403
Estimated Expiration: ⤷ Sign Up
Patent: 90415
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 88403
Estimated Expiration: ⤷ Sign Up
Patent: 90415
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 111
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 88403
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1991326
Estimated Expiration: ⤷ Sign Up
Patent: 1991327
Estimated Expiration: ⤷ Sign Up
Patent: 2129247
Estimated Expiration: ⤷ Sign Up
Patent: 140047599
Estimated Expiration: ⤷ Sign Up
Patent: 180100453
Estimated Expiration: ⤷ Sign Up
Patent: 190072665
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 32009
Estimated Expiration: ⤷ Sign Up
Patent: 57549
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering OLINVYK around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| New Zealand | 713143 | Opioid receptor ligands and methods of using and making same | ⤷ Sign Up |
| Israel | 272165 | ליגנדים של קולטן אופיואיד ושיטות לשימוש בהם ולהכנתם (Opioid receptor ligands and methods of using and making same) | ⤷ Sign Up |
| Canada | 2830742 | OXANES SUBSTITUES COMME LIGANDS DE RECEPTEUR OPIOIDE ET METHODES D'UTILISATION ET DE FABRICATION ASSOCIEES (SUBSTITUTED OXANES AS OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME) | ⤷ Sign Up |
| Japan | 2021176885 | オピオイド受容体リガンド並びにそれらの使用方法及び製造方法 (OPIOID RECEPTOR LIGAND AND METHODS OF USING AND MAKING THE SAME) | ⤷ Sign Up |
| Hong Kong | 1250984 | 阿片樣物質受體配體以及使用和製備其的方法 (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME) | ⤷ Sign Up |
| Brazil | 112013024136 | ligandos de receptor de opióide e métodos de usar e fabricar os mesmos | ⤷ Sign Up |
| New Zealand | 615993 | Opioid receptor ligands and methods of using and making same | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
